Business
Seegnal's Investor Meet & Greet with Corporate CEO, Mr. Elad Bibi-Aviv
Seegnal's Investor Meet & Greet with Corporate CEO, Mr. Elad Bibi-Aviv Seegnal's Inve...
About this update from Seegnal Inc.
[{"type":"text","content":"\n\n\nSeegnal's Investor Meet & Greet with Corporate CEO, Mr. Elad Bibi-Aviv\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\nSeegnal's Investor Meet & Greet with Corporate CEO, Mr. Elad Bibi-Aviv\nCanada NewsWire\n\n\n/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/\nCALGARY, AB, Jan. 12, 2026 /CNW/ - (TSXV: SEGN), a global leader in clinical decision support solutions applying patient-centric medication safety standards, today announced that its Chief Executive Officer, Elad Bibi-Aviv, will host two virtual investor meetings on January 19, 2026. These online sessions will provide shareholders with an opportunity to meet Mr. Bibi-Aviv personally and hear his vision for Seegnal's future. In each meeting he will introduce himself, outline the Company's strategic direction, and answer questions from investors, fostering direct dialogue with the shareholder community.\nFor convenience, the first session will be conducted in the Hebrew language and the other in English. The Hebrew meeting is scheduled for January 19, 2026, from 7:00 to 8:00 PM Israel Standard Time (IST), and the English meeting from 1:30 to 2:30 PM Eastern Standard Time (EST) on the same day. Both meetings will be held via Microsoft Teams Meeting (links provided below).\nMr. Bibi-Aviv has emphasized that Seegnal's purpose-driven mission was a key motivator in joining the Corporate as Chief Executive Officer, and stated \"I joined Seegnal because I recognize it as a genuine opportunity to make a real impact — a mission I find deeply meaningful,\" he said. \"As demonstrated in the publication in The American Journal of Pharmacy Benefits, Vol. 9, No. 2 titled \"Large-Scale, Community-Based Trial of a Personalized Drug-Related Problem Rectification System\" and in the publication in Drug Safety, Vol.44: 661-668 titled \"Reducing Alert Fatigue While Improving Safety – Comparison of Medication Alerts from Two Commercial Applications in the USA\", the technology we have developed not only saves lives but also delivers signif...